Research lines

  • CAR-T cells against BCMA in multiple myeloma: prognostic factors related to their activity and development of a new generation of chimeric receptors

    Despite the available number of treatments for multiple myeloma, the majority of patients end up presenting refractoriness or relapse to all these therapeutic lines. In some CD19 positive hematological malignancies, the use of CART therapy is being studied with promising results. This therapy is based on the administration of autologous T lymphocytes genetically modified to redirect their antigenic specificity against the antigen of interest. Therefore, the introduction of this therapy in multiple myeloma is being evaluated through the use of CART directed against the BCMA antigen (B-cell maturation antigen), present in the tumor cells. Numerous doubts have emerged after the use of CART anti-BCMA, such as the role of soluble BCMA, the degree of BCMA expression in plasma cells, its role in the eradication of extramedullary disease, the relapse predictive capacity of B cell reconstitution or the likelihood of BCMA-negative relapse. In addition, one of the limitations of the use of this therapy is the difficulty that exists to maintain the effectiveness of CART over time. Therefore, the possibility of developing a new generation of CART is being studied.

  • Mechanisms of immune control involved in the progression after treatment in the multiple myeloma

    The main goal of our research is to identify immunoregulatory molecules involved in multiple myeloma progression after current treatment. A better understanding of their functional roles will contribute to the development of new therapeutic strategies. We are investigating gene and protein expression in bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma in different disease stages. Based on our lab findings, we will evaluate therapeutic approaches against relevant targets in bone marrow culture assays. Blockade of inhibitory immunoregulatory molecules or activation of stimulatory receptors with agonistic antibodies will allow us to develop targeted therapies to delay or to avoid myeloma progression.

  • MicroRNA profile in bone marrow mesenchymal stromal cells from patients with multiple myeloma in different status disease

    Multiple myeloma is a malignant disorder characterized by the neoplastic growth of bone marrow plasma cells, where the bone marrow microenvironment plays a crucial role. The crosstalk between myeloma and surrounding cells, such as mesenchymal stromal cells (MSCs), endothelial cells and immune cells, is crucial for pathogenesis. In addition to conventional signaling pathways, which include cell adhesion and the release of soluble factors, extracellular vesicles contribute to the modulation of the bone marrow microenvironment to favor tumor formation without the need for direct contact with non-tumor cells. The exchange of these vesicles, which contain proteins, mRNA, lipids and microRNAs (miRNAs) mainly, is bidirectional.. Our aim is to define miRNAs and their targets that help us to better known the tumor control and/or progression related to MSC. We will assess the possible effect of treatment and response in the miRNA expression in order to identify potential biomarkers in bone marrow and serum for monitoring the response and to predict relapse.